Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Cited by (1,004)

Items 101–200 of 1,004

1. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
   Ray, Kausik K., Stoekenbroek, Robert M., Kallend, David, Nishikido, Toshiyuki, Leiter, Lawrence A., Landmesser, Ulf, Wright, R. Scott, Wijngaard, Peter L. J., Kastelein, John J. P. · 2019 · JAMA Cardiology
2. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
   Ference, Brian A, Cannon, Christopher P, Landmesser, Ulf, Lüscher, Thomas F, Catapano, Alberico L, Ray, Kausik K · 2018 · European Heart Journal
3. Statins and PCSK9 inhibitors: A new lipid-lowering therapy
   Gallego-Colon, Enrique, Daum, Aner, Yosefy, Chaim · 2020 · European Journal of Pharmacology
4. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)
   F. Piepoli, Massimo · 2017 · International Journal of Behavioral Medicine
5. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk
   Ulf Landmesser, M. John Chapman, Michel Farnier, Bariş Gencer, Stephan Gielen, G. Kees Hovingh, Thomas Felix Lüscher, David Sinning, Lale S Tokgözoğlu, Olov Wiklund et al. · 2016 · European Heart Journal
6. Myotoxicity of statins: Mechanism of action
   Patrick du Souich, Ghislaine O. Roederer, Robert Dufour · 2017 · Pharmacology & Therapeutics
7. Surprises from genetic analyses of lipid risk factors for atherosclerosis
   Musunuru, Kiran, Kathiresan, Sekar · 2016 · Circulation Research
8. Prognostic value of PCSK9 levels in patients with acute coronary syndromes
   Bariş Gencer, Fabrizio Montecucco, David Nanchen, Federico Carbone, Roland Klingenberg, Nicolas Vuilleumier, Soheila Aghlmandi, Dik Heg, Lorenz Räber, Reto Auer et al. · 2015 · European Heart Journal
9. 2017 Taiwan lipid guidelines for high risk patients
   Yi‐Heng Li, Kwo‐Chang Ueng, Jiann‐Shing Jeng, Min‐Ji Charng, Tsung‐Hsien Lin, Kuo‐Liong Chien, Chih‐Yuan Wang, Ting‐Hsing Chao, Ping‐Yen Liu, Cheng‐Huang Su et al. · 2017 · Journal of the Formosan Medical Association
10. Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule
    Motasim Jawi, Jiri J Frohlich, Sammy Chan · 2020 · Journal of Lipids
11. Targeting PCSK9 to tackle cardiovascular disease
    Hummelgaard, Sandra, Vilstrup, Joachim Pold, Gustafsen, Camilla, Glerup, Simon, Weyer, Kathrin · 2023 · Pharmacology & Therapeutics
12. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1
    Ray, Kausik K., Stoekenbroek, Robert M., Kallend, David, Leiter, Lawrence A., Landmesser, Ulf, Wright, R. Scott, Wijngaard, Peter, Kastelein, John J.P. · 2018 · Circulation
13. Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms
    Rusu, Victor, Hoch, Eitan, Mercader, Josep M., Tenen, Danielle E., Gymrek, Melissa, Hartigan, Christina R., DeRan, Michael, von Grotthuss, Marcin, Fontanillas, Pierre, Spooner, Alexandra et al. · 2017 · Cell
14. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
    Gregg C. Fonarow, ANTHONY C. KEECH, Terje Rolf Pedersen, Robert Patrick Giugliano, Peter S. Sever, Peter Lindgren, Ben van Hout, Guillermo Villa, Yi Qian, Ransi M. Somaratne et al. · 2017 · JAMA Cardiology
15. Poly-ADP-ribosylation in health and disease
    Marie-Ève Bonicalzi, Jean-François Haince, Arnaud Droit, Guy G. Poirier · 2005 · Cellular and Molecular Life Sciences
16. Cardiovascular risk and dyslipidemia among persons living with HIV: a review
    Paolo Maggi, Antonio Di Biagio, Stefano Rusconi, Stefania Cicalini, Maurizio D’Abbraccio, Gabriella d’Ettorre, Canio Vito Martinelli, Giuseppe Nunnari, Laura Sighinolfi, Vincenzo Spagnuolo et al. · 2017 · BMC Infectious Diseases
17. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis
    Khan, Safi U, Yedlapati, Siva H, Lone, Ahmad N, Hao, Qiukui, Guyatt, Gordon, Delvaux, Nicolas, Bekkering, Geertruida E (Trudy), Vandvik, Per Olav, Riaz, Irbaz Bin, Li, Sheyu et al. · 2022 · BMJ
18. A cholesterol-lowering VLP vaccine that targets PCSK9
    Erin Crossey, Marcelo J. Amar, Maureen L. Sampson, Julianne Peabody, John T. Schiller, Bryce Chackerian, Alan Thomas Remaley · 2015 · Vaccine
19. Effect of Alirocumab on Mortality After Acute Coronary Syndromes
    Philippe Gabríel Steg, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, Marie-France Brégeault, Anthony J. Dalby, Rafael Díaz, Jay M. Edelberg, Shaun G. Goodman, Corinne Hanotin et al. · 2019 · Circulation
20. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
    Giuseppe Danilo Norata, Hagai Tavori, Angela Pirillo, Sergio Fazio, Alberico Luigi Catapano · 2016 · Cardiovascular Research
21. Vascular inflammation and low‐density lipoproteins: is cholesterol the link? A lesson from the clinical trials
    Alberico Luigi Catapano, Angela Pirillo, Giuseppe Danilo Norata · 2017 · British Journal of Pharmacology
22. Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS
    Takuji Yamauchi, Takeshi Masuda, Matthew C. Canver, Michael Seiler, Yuichiro Semba, Mohammad Shboul, Mohammed Al‐Raqad, Manami Maeda, Vivien A. C. Schoonenberg, Mitchel A. Cole et al. · 2018 · Cancer Cell
23. MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations
    Gibran Hemani, Jie Zheng, Kaitlin Hazel Wade, Charles Laurin, Benjamin Elsworth, Stephen Burgess, Jack Bowden, Ryan Langdon, Vanessa Y. Tan, James Yarmolinsky et al. · 2016 · bioRxiv (Cold Spring Harbor Laboratory)
24. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
    Peter W.F. Wilson, Tamar S. Polonsky, Michael D. Miedema, Amit Khera, Andrzej Stanislaw Kosinski, Jeffrey T. Kuvin · 2019 · Circulation
25. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
    Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P. · 2018 · Clinical Pharmacokinetics
26. Protective alleles and modifier variants in human health and disease
    Andrew Robert Harper, Shalini Nayee, Eric J. Topol · 2015 · Nature Reviews Genetics
27. Lipoprotein apheresis to treat elevated lipoprotein (a)
    Elisa Waldmann, Klaus Georg Parhofer · 2016 · Journal of Lipid Research
28. Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT
    John Adams Jarcho, John F. Keaney · 2015 · New England Journal of Medicine
29. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
    Nathanael G. Lintner, Kim F. McClure, Donna N. Petersen, Allyn T. Londregan, David W. Piotrowski, Liuqing Wei, Jun Xiao, Michael W. Bolt, Paula M. Loria, Bruce A. Maguire et al. · 2017 · PLoS Biology
30. Coronary Atherosclerotic Phenotype and Plaque Healing in Patients With Recurrent Acute Coronary Syndromes Compared With Patients With Long-term Clinical Stability
    Rocco Vergallo, Italo Porto, Domenico D’Amario, Gianmarco Annibali, Mattía Galli, Stefano Benenati, Francesco Bendandi, Stefano Migliaro, Francesco Fracassi, Cristina Aurigemma et al. · 2019 · JAMA Cardiology
31. Determining When to Add Nonstatin Therapy
    Jennifer G. Robinson, Roeland Huijgen, Kausik Kumar Ray, Jane E. Persons, John J.P. Kastelein, Michael J. Pencina · 2016 · Journal of the American College of Cardiology
32. Lipid lowering therapy and circulating PCSK9 concentration
    Nozue, Tsuyoshi · 2017 · Journal of Atherosclerosis and Thrombosis
33. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
    Paul Barton Duell, Raul Dias Santos, Bridget‐Anne Kirwan, Joseph Lee Witztum, Sotirios Tsimikas, John J.P. Kastelein · 2016 · Journal of clinical lipidology
34. The evolution of domain arrangements in proteins and interaction networks
    Erich Bornberg‐Bauer, Francois Beaussart, Sarah Kummerfeld, Sarah Amalia Teichmann, January Mikolaj Weiner · 2005 · Cellular and Molecular Life Sciences
35. Hypercholesterolaemia and vascular dementia
    Jason P. Appleton, Polly Scutt, Nikola Sprigg, Philip M. Bath · 2017 · Clinical Science
36. PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo
    Villard, Elise F., Thedrez, Aurélie, Blankenstein, Jorg, Croyal, Mikaël, Tran, Thi-Thu-Trang, Poirier, Bruno, Le Bail, Jean-Christophe, Illiano, Stéphane, Nobécourt, Estelle, Krempf, Michel et al. · 2016 · JACC: Basic to Translational Science
37. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years
    de Carvalho, Luiz Sérgio F., Campos, Alessandra M., Sposito, Andrei C. · 2018 · Diabetes Care
38. Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management
    Konstantinos Dean Boudoulas, Filippos K. Triposkiadis, Paraschos Geleris, Harisios K Boudoulas · 2016 · Progress in Cardiovascular Diseases
39. Circulating Lipoprotein Lipids, Apolipoproteins and Ischemic Stroke
    Shuai Yuan, Bowen Tang, Jie Zheng, Susanna C. Larsson · 2020 · Annals of Neurology
40. An oral antisense oligonucleotide for PCSK9 inhibition
    Peter Gennemark, Katrin Walter, Niclas Clemmensen, Dinko Rekić, Catarina A.M. Nilsson, Jane Knöchel, Mikko Hölttä, Linda C Wernevik, Birgitta E. Rosengren, Dorota Kakol‐Palm et al. · 2021 · Science Translational Medicine
41. Immune cell screening of a nanoparticle library improves atherosclerosis therapy
    Jun Tang, Samantha Baxter, Arjun A. Menon, Amr Alaarg, Brenda L. Sánchez-Gaytán, François Fay, Yiming Zhao, Mireille I. Ouimet, Mounia Sabrina Braza, Valerie A. Longo et al. · 2016 · Proceedings of the National Academy of Sciences
42. Management of diabetic dyslipidemia: An update
    Ishwarlal Jialal, Gurdeep Singh · 2019 · World Journal of Diabetes
43. The proprotein convertases in hypercholesterolemia and cardiovascular diseases: Emphasis on proprotein convertase subtilisin/kexin 9
    Seidah, Nabil G., Abifadel, Marianne, Prost, Stefan, Boileau, Catherine, Prat, Annik · 2017 · Pharmacological Reviews
44. Vulnerable Plaque, Characteristics, Detection, and Potential Therapies
    Anouar Hafiane · 2019 · Journal of Cardiovascular Development and Disease
45. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities
    Alpo F. Vuorio, Gerald Francis Watts, Wolfgang J. Schneider, Sotirios Tsimikas, Petri T. Kovanen · 2019 · Journal of Internal Medicine
46. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
    Camilla Gustafsen, Ditte Olsen, Joachim Vilstrup, Signe Lund, Anika Reinhardt, Niels Wellner, Torben Larsen, Christian Brix Folsted Andersen, Kathrin Weyer, Jin‐Ping Li et al. · 2017 · Nature Communications
47. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
    Leiter, Lawrence A., Teoh, Hwee, Kallend, David, Wright, R. Scott, Landmesser, Ulf, Wijngaard, Peter L.J., Kastelein, John J.P., Ray, Kausik K. · 2019 · Diabetes Care
48. Effect of monoclonal antibodies to PCSK9 on high‐sensitivity C‐reactive protein levels: a meta‐analysis of 16 randomized controlled treatment arms
    Sahebkar, Amirhossein, Di Giosia, Paolo, Stamerra, Cosimo Andrea, Grassi, Davide, Pedone, Claudio, Ferretti, Gianna, Bacchetti, Tiziana, Ferri, Claudio, Giorgini, Paolo · 2016 · British Journal of Clinical Pharmacology
49. Genetics: Implications for Prevention and Management of Coronary Artery Disease
    Themistocles L. Assimes, Robert Roberts · 2016 · Journal of the American College of Cardiology
50. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective
    Neil B. Lineberry, Jesse A. Berlin, Bernadette A. Mansi, Susan C. Glasser, Michael Berkwits, Christian Klem, Ananya Bhattacharya, Leslie Citrome, Robert E. Enck, John Fletcher et al. · 2016 · BMJ
51. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
    Kiyosue, Arihiro, Honarpour, Narimon, Kurtz, Christopher, Xue, Allen, Wasserman, Scott M., Hirayama, Atsushi · 2016 · The American Journal of Cardiology
52. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
    Hagai Tavori, Ilaria Giunzioni, Irene Marta Predazzi, Deanna L. Plubell, Anna Shivinsky, Joshua Miles, Rachel M. DeVay, Liang Hong, Shirya Rashid, MacRae F. Linton et al. · 2016 · Cardiovascular Research
53. Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
    Sliz, Eeva, Kettunen, Johannes, Holmes, Michael V., Williams, Clare Oliver, Boachie, Charles, Wang, Qin, Männikkö, Minna, Sebert, Sylvain, Walters, Robin, Lin, Kuang et al. · 2018 · Circulation
54. Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
    Toru Hiyoshi, Mutsunori Fujiwara, Yao Zemin · 2018 · Journal of Biomedical Research
55. 2023 China Guidelines for Lipid Management
    Jian‐Jun Li, Shui‐Ping Zhao, Dong Zhao, Guoping Lü, Daoquan Peng, Jing Liu, Zhen‐Yue Chen, Yuan‐Lin Guo, Na‐Qiong Wu, Sheng-kai Yan et al. · 2023 · 老年心脏病学杂志：英文版
56. Potential therapeutic effects of mTOR inhibition in atherosclerosis
    Ammar Kurdi, Guido R.Y. De Meyer, Wim Martinet · 2015 · British Journal of Clinical Pharmacology
57. Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
    Thorsten Kessler, Heribert Schunkert · 2021 · JACC Basic to Translational Science
58. Untitled work
    Hlatky Mark · 2017 · 10.1016/j.jacc.2017.10.001
59. PCSK9 and cancer: Rethinking the link
    Khadijeh Mahboobnia, Matteo Pirro, Ettore Marini, Francesco Grignani, Evgeny E. Bezsonov, Tannaz Jamialahmadi, Amirhossein Sahebkar · 2021 · Biomedicine & Pharmacotherapy
60. Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
    Isabella Hetherington, Hana Totary-Jain · 2022 · Molecular Therapy
61. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement
    Nicola Ferri, Silvia Marchianò, Gianpaolo Tibolla, Roberta Baetta, A. Dhyani, Massimiliano Ruscica, Patrizia Uboldi, Alberico Luigi Catapano, Alberto Corsini · 2016 · Atherosclerosis
62. Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
    Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association · 2021 · Cardiology Discovery
63. Management of patients with familial hypercholesterolaemia
    Željko Reiner · 2015 · Nature Reviews Cardiology
64. A systematic review of PCSK9 inhibitors alirocumab and evolocumab
    McDonagh, Marian, Peterson, Kim, Holzhammer, Brittany, Fazio, Sergio · 2016 · Journal of Managed Care & Specialty Pharmacy
65. Prevention of Cardiovascular Disease
    Brian V Reamy, P. Michele Williams, Daniel P. Kuckel · 2018 · Primary Care Clinics in Office Practice
66. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
    Carl E. Orringer, Terry A. Jacobson, Joseph J. Saseen, Alan S. Brown, Antonio M. Gotto, Joyce L. Ross, James A. Underberg · 2017 · Journal of clinical lipidology
67. Oestrogen-modulated gene expression in the human endometrium
    Chamindie Punyadeera, H.H.N.M. Dassen, Jan P.G. Klomp, G.A.J. Dunselman, Rick Kamps, Fred A. Dijcks, A. G. H. EDERVEEN, Anton F.P.M. de Goeij, Patrick G. Groothuis · 2005 · Cellular and Molecular Life Sciences
68. Can LDL cholesterol be too low? Possible risks of extremely low levels
    ANDERS G. OLSSON, Bo Angelin, Gerd Assmann, Christoph J. Binder, Ingemar Björkhem, Ángel Cedazo-Mı́nguez, Jonathan C. Cohen, Arnold von Eckardstein, Eduardo Farinaro, Dirk Müller‐Wieland et al. · 2017 · Journal of Internal Medicine
69. Current therapies for lowering lipoprotein (a)
    Julian C. van Capelleveen, Fleur M. van der Valk, Erik S.G. Stroes · 2015 · Journal of Lipid Research
70. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
    Peter H. Jones, Harold Edward Bays, Umesh Chaudhari, Robert C. Pordy, Christelle Lorenzato, Kathryn Miller, Jennifer G. Robinson · 2016 · The American Journal of Cardiology
71. A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation
    Donna N. Petersen, Julie Hawkins, Wanida Ruangsiriluk, Kimberly A. Stevens, Bruce A. Maguire, Thomas N. O’Connell, Benjamin N. Rocke, Markus Boehm, Roger B. Ruggeri, Tim Rolph et al. · 2016 · Cell chemical biology
72. Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
    Green Ahn, Steven M. Banik, Carolyn Ruth Bertozzi · 2021 · Cell chemical biology
73. A Comprehensive Review of PCSK9 Inhibitors
    Caroline Coppinger, Mohammad Reza Movahed, Veronica Azemawah, Lee Peyton, James Gregory, Mehrnoosh Hashemzadeh · 2022 · Journal of Cardiovascular Pharmacology and Therapeutics
74. Signaling cascades in the failing heart and emerging therapeutic strategies
    Xin He, Tailai Du, Tianxin Long, Xinxue Liao, Yugang Dong, Zhan‐Peng Huang · 2022 · Signal Transduction and Targeted Therapy
75. Evidence-based goals in LDL-C reduction
    Soran, Handrean, Dent, Ricardo, Durrington, Paul · 2017 · Clinical Research in Cardiology
76. Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
    Simon Glerup, Rainer Schulz, Ulrich Laufs, Klaus‐Dieter Schlüter · 2017 · Basic Research in Cardiology
77. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
    Alba Carreras, Luna Simona Pane, Roberto Nitsch, Katja Madeyski-Bengtson, Michelle J. Porritt, Pınar Akçakaya, Amir Taheri‐Ghahfarokhi, Elke Ericson, Mikael Bjursell, Marta Pérez-Alcázar et al. · 2019 · BMC Biology
78. The perils of surrogate endpoints
    William S. Weintraub, Thomas Felix Lüscher, Stuart Pocock · 2015 · European Heart Journal
79. Bioinspired yeast microcapsules loaded with self-assembled nanotherapies for targeted treatment of cardiovascular disease
    Xiangjun Zhang, Xiaoqiu Xu, Yidan Chen, Yin Dou, Xing Wang Zhou, Lanlan Li, Chenwen Li, Huijie An, Hui Tao, Houyuan Hu et al. · 2017 · Materials Today
80. ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
    Lieven Annemans, Chris J. Packard, Andrew H. Briggs, Kausik Kumar Ray · 2017 · European Heart Journal
81. Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study
    Pankaj Kumar Arora, Rajat Kalra, PETER W. CALLAS, Kristine Alexander, Neil A. Zakai, Virginia G. Wadley, Garima Arora, Brett M. Kissela M. D, Suzanne E. Judd, Mary Cushman · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
82. Management of residual risk after statin therapy
    Christina A. Reith, Jane Armitage · 2015 · Atherosclerosis
83. Lipoprotein(a) Interactions With Low‐Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS)
    Mehdi Shahriyari Afshar, Louise Pilote, Line Dufresne, James C. Engert, George Thanassoulis · 2016 · Journal of the American Heart Association
84. Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
    Angelos D. Karagiannis, Martin Liu, Peter Paul Toth, Shijia Zhao, Devendra K. Agrawal, Peter Libby, Yiannis S. Chatzizisis · 2018 · Current Atherosclerosis Reports
85. Low levels of low-density lipoprotein cholesterol and cognitive decline
    Rong Hua, Yanjun Ma, Chenglong Li, Bao‐Liang Zhong, Wuxiang Xie · 2021 · 中国科学通报：英文版
86. The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
    Emmer, Brian T, Hesketh, Geoffrey G, Kotnik, Emilee, Tang, Vi T, Lascuna, Paul J, Xiang, Jie, Gingras, Anne-Claude, Chen, Xiao-Wei, Ginsburg, David · 2018 · eLife
87. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
    Peter Edward Penson, D. Leann Long, George Howard, Peter Paul Toth, Paul Muntner, Virginia J. Howard, Monica M. Safford, Steven Richard Jones, Seth Shay Martin, Mohsen Mazidi et al. · 2018 · European Heart Journal
88. PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
    Julius L. Katzmann, Ioanna Gouni‐Berthold, Ulrich Laufs · 2020 · Frontiers in Physiology
89. Using human genetics to improve safety assessment of therapeutics
    Keren Carss, Aimée M. Deaton, Alberto Del Río-Espínola, Dorothée Diogo, Mark R. Fielden, Diptee A. Kulkarni, Jonathan G. Moggs, Peter Newham, Matthew R. Nelson, Frank D. Sistare et al. · 2022 · Nature Reviews Drug Discovery
90. A Therapeutic Peptide Vaccine Against PCSK9
    Yajie Pan, Yanzhao Zhou, Hailang Wu, Xiao Chen, Xiajun Hu, Hongrong Zhang, Zihua Zhou, Zhihua Qiu, Yuhua Liao · 2017 · Scientific Reports
91. Cost‐Effectiveness of LDL ‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
    Shravanthi R. Gandra, Guillermo Villa, Gregg C. Fonarow, Mickael Löthgren, Peter Lindgren, Ransi M. Somaratne, Ben van Hout · 2016 · Clinical Cardiology
92. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies
    Felice Gragnano, Paolo Calabrò · 2018 · Atherosclerosis
93. Epidemiology of Dementia: The Burden on Society, the Challenges for Research
    Frank J. Wolters, M. Arfan Ikram · 2018 · Methods in molecular biology
94. PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites
    Kent, Shia T., Rosenson, Robert S., Avery, Christy L., Chen, Yii-Der I., Correa, Adolfo, Cummings, Steven R., Cupples, L. Adrienne, Cushman, Mary, Evans, Daniel S., Gudnason, Vilmundur et al. · 2017 · Circulation: Cardiovascular Genetics
95. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
    Philip D. Harvey, Marwan Noel Sabbagh, John Harrison, Henry N. Ginsberg, M. John Chapman, Garen Z. Manvelian, Angèle Moryusef, Jonas Mandel, Michel Farnier · 2017 · European Heart Journal
96. PCSK9 inhibitors for treating hypercholesterolemia
    Andrea Pasta, Anna Laura Cremonini, Livia Pisciotta, Angelo Buscaglia, Italo Porto, Fabio Barra, Simone Ferrero, Claudio Brunelli, Gian Marco Rosa · 2020 · Expert Opinion on Pharmacotherapy
97. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
    Yehuda Handelsman, Norman E. Lepor · 2018 · Journal of the American Heart Association
98. Statin-associated muscle symptoms—Managing the highly intolerant
    James M. Backes, Janelle F. Ruisinger, Cheryl Gibson, Patrick M. Moriarty · 2017 · Journal of clinical lipidology
99. The Treatment of Disorders of Lipid Metabolism
    Klaus Georg Parhofer · 2016 · Deutsches Ärzteblatt international
100. PCSK9 inhibition in the management of familial hypercholesterolemia
     Ogura, Masatsune · 2018 · Journal of Cardiology